1. Volume 14, Issue 9, Pages 1382-1387 (September 2017)
Characterization of health care utilization in patients receiving implantable cardioverter- defibrillator therapies: An analysis of the managed ventricular pacing trial 
John Rickard, MD, MPH, David Whellen, MD, MPH, FHRS, Lou Sherfesee, PhD, Brett J. Peterson, BS, Tara Nahey, DVM, PhD, Anthony S. Tang, MD, FHRS, Kenneth A. Ellenbogen, MD, FHRS, Alan Cheng, MD 
Heart Rhythm 
Volume 14, Issue 9, Pages (September 2017)
DOI: /j.hrthm
Copyright © 2017 The Authors Terms and Conditions

2. Figure 1
Annual rates for HCUs in each of the 6 periods after the implant procedure. Only HCUs relatedness to VTA, ICD therapy, heart failure, implant procedure, or the ICD system are included. HCU = health care utilization; ICD = implantable cardioverter-defibrillator; VTA = ventricular tachyarrhythmia.
Heart Rhythm  , DOI: ( /j.hrthm )
Copyright © 2017 The Authors Terms and Conditions

3. Figure 2
Cumulative incidence rate for first VTA, VTA treated with antitachycardia pacing or shock, VTA treated with shock, VTA-related HCU, and shocked VTA-related HCU accounting for competing risk of mortality. HCU = health care utilization; VTA = ventricular tachyarrhythmia.
Heart Rhythm  , DOI: ( /j.hrthm )
Copyright © 2017 The Authors Terms and Conditions